Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

zirconium Zr 89-DFO-YS5

A radioimmunoconjugate containing YS5, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface antigen cluster of differentiation 46 (CD46; membrane cofactor protein; MCP), and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon administration, the monoclonal antibody moiety of zirconium Zr 89-DFO-YS5 specifically targets and binds to a conformational epitope formed within Sushi domains (complement control protein repeats; CCPs) 1 and 2 on the immune modulatory receptor CD46 expressed on certain tumor cells. Upon binding, internalization and PET, CD46-expressing tumor cells can be imaged and assessed. The conformational epitope on CD46 is highly expressed in multiple tumor cell types while minimally expressed or absent in normal, healthy tissues. CD46 plays a key role in the negative regulation of innate immunity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:(89)Zr-DFO-YS5
89Zr DFO-YS5
89Zr-DFO-YS5
Zr 89-DFO-YS5
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search